Evidence map›Paper›PMID 37074725›Full record

ArticleChemical research in toxicology2023

Characterization of Drug-Specific CD4

Kanoot Jaruthamsophon, Paul J Thomson, Sean Hammond, Eunice Zhang, Ana Alfirevic, Chonlaphat Sukasem, Dean J Naisbitt, Munir Pirmohamed

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chemical research in toxicology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Kanoot JaruthamsophonCentre for Drug Safety Science, Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool L69 3GE, U.K.ORCID 0000-0003-1563-0024
Paul J ThomsonCentre for Drug Safety Science, Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool L69 3GE, U.K.
Sean HammondCentre for Drug Safety Science, Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool L69 3GE, U.K.
Eunice ZhangCentre for Drug Safety Science, Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool L69 3GE, U.K.
Ana AlfirevicCentre for Drug Safety Science, Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool L69 3GE, U.K.
Chonlaphat SukasemCentre for Drug Safety Science, Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool L69 3GE, U.K.
Dean J NaisbittCentre for Drug Safety Science, Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool L69 3GE, U.K.ORCID 0000-0003-4107-7832
Munir PirmohamedCentre for Drug Safety Science, Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool L69 3GE, U.K.
University of Liverpool · GBAstraZeneca (United Kingdom) · GBPrince of Songkla University · TH

Funding

Medical Research Council G0700654Medical Research Council MR/R009635/1
6 · The paper itself

Abstract

Carbamazepine (CBZ) is an aromatic anticonvulsant known to cause drug hypersensitivity reactions, which range in severity from relatively mild maculopapular exanthema to potentially fatal Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN). These reactions are known to be associated with human leukocyte antigen (HLA) class I alleles, and CBZ interacts preferentially with the related HLA proteins to activate CD8

Indexed as

Drug HypersensitivityStevens-Johnson SyndromeAnticonvulsantsCarbamazepineCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesHLA AntigensHLA-B AntigensHLA-DRB1 ChainsHumansAnticonvulsantsCarbamazepineHLA AntigensHLA-B AntigensHLA-DRB1 Chains

Identifiers

PMID37074725
PMCPMC10189794
OpenAlexW4366351713

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.